<DOC>
	<DOC>NCT01791192</DOC>
	<brief_summary>This study will assess the safety, tolerability, and efficacy of FTY720 in patients with acute, noninfectious intermediate, posterior and pan uveitis</brief_summary>
	<brief_title>Study of FTY720 in Patients With Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Panuveitis</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Acute noninfectious posterior, intermediate, or pan uveitis Vitreous haze score of 1+ or more in the study eye at screening and baseline visits Vasoocclusive vasculitis involving the retinal macula Beh√ßet's uveitis Patients requiring corticosteroid or another systemic immunosuppressive medication for any other disease (e.g., asthma or some other autoimmune disease) that would contraindicate tapering (topical steroids permitted) Other protocol defined inclusions and/or exclusions may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Uveitis, Fingolimod, Phase II, Visual Acuity, Vitreous Haze, OCT</keyword>
</DOC>